|Title:||Composition and method for treatment of CMV retinites|
|Abstract:||This invention concerns compositions and methods for the treatment of CMV infections. A composition including an antisense oligonucleotide targeted to the IE2 gene of CMV and a pharmaceutically acceptable carrier were used stop progression in CMV retinitis.|
|Inventor(s):||Draper; Kenneth G. (Boulder, CO), Chapman; Sharon K. (Carlsbad, CA), Kisner; Daniel L. (Cardiff, CA)|
|Assignee:||Isis Pharmaceuticals, Inc. (Carlsbad, CA)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Formulation;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|PCT/US91/05815||Aug 14, 1991|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.